Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) provided key business updates at the 43rd Annual J.P. Morgan Healthcare Conference. The company projects over $1 billion in net sales for 2025 from its two main products, NUPLAZID and DAYBUE.

Key developments include the submission of a marketing authorization application for DAYBUE to the European Medicines Agency (EMA), with expected approval in Q1 2026. The company plans to initiate Managed Access Programs in Europe by Q2 2025, marking its first international revenue stream.

Pipeline milestones for 2025-2026 include: completion of COMPASS PWS Phase 3 study enrollment for ACP-101 in Prader-Willi Syndrome (Q4 2025), RADIANT Phase 2 study completion for ACP-204 in Alzheimer's disease psychosis (Q1 2026), and initiation of a Phase 2 study for ACP-204 in Lewy Body Dementia (Q3 2025). The company will host its first R&D Day in mid-2025.

Positive

• Projected net sales to exceed $1 billion in 2025
• European market expansion with DAYBUE submission to EMA
• First international revenue expected in Q2 2025 through Managed Access Programs
• Multiple late-stage clinical trials advancing toward completion

Negative

• None.

Insights

Financial Analyst

The most compelling aspect of this update is Acadia's projected milestone of exceeding $1 billion in net sales for 2025, driven by NUPLAZID and DAYBUE. The European expansion strategy through the DAYBUE marketing authorization application and Managed Access Programs represents a significant revenue diversification opportunity. The pipeline progress, particularly in Prader-Willi Syndrome and Alzheimer's disease psychosis, positions the company for potential value creation in 2026.

The focus on positive cash flow generation alongside top-line growth suggests improving operational efficiency. The rare disease market penetration combined with CNS portfolio development presents a balanced growth strategy that could reduce revenue concentration risk.

Market Research Analyst

The European market entry strategy is particularly noteworthy as it marks Acadia's first international revenue stream. The Managed Access Program in Q2 2025 could provide early revenue ahead of full EMA approval in Q1 2026, demonstrating strategic market access planning. The company's dual-franchise approach with NUPLAZID and DAYBUE in distinct therapeutic areas (Parkinson's disease psychosis and Rett syndrome) provides revenue diversification and multiple growth vectors.

The pipeline development in Prader-Willi Syndrome and Alzheimer's disease psychosis targets substantial market opportunities with significant unmet needs. The planned R&D Day in mid-2025 typically signals confidence in pipeline progress and could serve as a catalyst for investor interest.

Medical Research Analyst

The advancement of ACP-101 in Prader-Willi Syndrome Phase 3 study (COMPASS PWS) and ACP-204 in Alzheimer's disease psychosis Phase 2 study (RADIANT) represents strategic targeting of high-unmet-need indications. The expansion into Lewy Body Dementia with ACP-204 demonstrates efficient pipeline utilization through indication expansion. The company's focus on neuropsychiatric symptoms across central nervous system disorders suggests a cohesive R&D strategy leveraging existing expertise.

The development timeline with multiple readouts in 2026 creates a steady news flow that could drive investor interest. The combination of commercial products and late-stage pipeline assets provides both near-term revenue and future growth potential.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

“2025 is shaping up to be an exciting year as we build on the success of our two growing brands, NUPLAZID and DAYBUE, which together are projected to generate more than $1 billion in net sales this year,” said Catherine Owen Adams, Chief Executive Officer. “In addition to growing our strong commercial franchises, we are laying the foundation for future growth through global expansion and pipeline advancement. Today, we announced our submission of a marketing authorization application for DAYBUE with the European Medicines Agency and anticipate beginning Managed Access Program–related sales in Europe as early as the second quarter. We are also pleased to share updates on our R&D pipeline—both today and at our first R&D Day in mid-2025—as our lead programs near data readouts. By expanding our reach beyond the U.S. and continuing to advance our pipeline, we believe Acadia is poised for sustained top-line growth and increasing positive cash flow.”

Key 2025-2026 Milestones:

• Announced today that the marketing authorization application for DAYBUE^™ has been submitted to the European Medicines Agency (EMA) with expected approval in the first quarter of 2026.
• Initiation of Managed Access Programs in Europe in the second quarter of 2025, potentially resulting in the Company’s first revenues from outside the U.S.
• Enrollment of the last patient in the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome anticipated in the fourth quarter of 2025, followed by top-line results announcement in the first half of 2026.
• Enrollment of the last patient in the RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis expected in the first quarter of 2026, followed by top-line results announcement in mid-2026.
• Initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia in the third quarter of 2025.
• The Company will host its first ever R&D Day in mid-2025.
• Annual net sales for the full-year 2025 expected to exceed $1 billion for the first time in Company history.

Today’s presentation will take place at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization, and expected regulatory timelines for trofinetide in the EU; (iii) plans for our pipeline, including the timing and conduct of our clinical trials, anticipated enrollment milestones and the timing and results of data from our clinical trials; and (iv) our estimates regarding our future financial performance, profitability and capital requirements, including our full year 2024 financial guidance and potential achievement of our milestone of annualized net sales in 2025. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of NUPLAZID^® and DAYBUE and our ability to maintain or increase sales of NUPLAZID or DAYBUE; our plans to commercialize DAYBUE outside the U.S., including in Canada; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our quarterly report on Form 10-Q quarter ended September 30, 2024, filed with the SEC on November 7, 2024, available at www.sec.gov. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114304564/en/

Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.

FAQ

What is ACAD's projected revenue for 2025?

Acadia Pharmaceuticals projects net sales to exceed $1 billion in 2025, driven by its two main products NUPLAZID and DAYBUE.

When will ACAD's DAYBUE receive EMA approval?

DAYBUE is expected to receive European Medicines Agency (EMA) approval in the first quarter of 2026.

When will ACAD begin generating international revenue?

Acadia expects to begin generating its first international revenues through Managed Access Programs in Europe starting in the second quarter of 2025.

What are the key clinical trial milestones for ACAD in 2025-2026?

Key milestones include completing enrollment for COMPASS PWS Phase 3 study in Q4 2025, RADIANT Phase 2 study completion in Q1 2026, and initiating Phase 2 study for Lewy Body Dementia in Q3 2025.

When will ACAD announce results from its COMPASS PWS Phase 3 study?

Acadia plans to announce top-line results from the COMPASS PWS Phase 3 study in the first half of 2026.